Enanta Pharmaceuticals, Inc. (ENTA) Stock Forecast
ENTA analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.83 / 5 from 6 analysts
- Price target
- $21.83 average of analyst targets
- Upside to target
- +96.7% from the latest close
- Next earnings
- November 16, 2026 EPS estimate $-0.82
- 52-week range
- $10.47 – $16.85
ENTA analyst ratings
6 analystsNumber of analysts at each rating.
ENTA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ENTA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.41 | −$0.48 | −$0.33 | −$0.42 | +3.6% | 2 |
| Current fiscal year (FY2026) | −$2.29 | −$2.49 | −$2.09 | −$3.84 | +40.3% | 4 |
| Next fiscal year (FY2027) | −$2.37 | −$3.08 | −$1.75 | −$2.29 | −3.6% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ENTA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next quarter (Dec '26) | $16.2M | $14.5M | $18.0M | −12.7% | 2 |
| Current fiscal year (FY2026) | $64.0M | $61.0M | $66.1M | −2.0% | 5 |
| Next fiscal year (FY2027) | $63.7M | $53.2M | $77.0M | −0.4% | 5 |
ENTA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ENTA revenue: reported and forecast
ENTA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next quarter (Dec '26) | −$0.36 | −$0.36 | −$0.36 | −$0.36 | −$0.41 | +11.0% | 0 up · 1 down |
| Current fiscal year (FY2026) | −$1.96 | −$1.91 | −$2.29 | −$2.29 | −$2.29 | +16.8% | 0 up · 2 down |
| Next fiscal year (FY2027) | −$1.98 | −$2.07 | −$2.37 | −$2.37 | −$2.37 | +20.2% | 0 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ENTA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ENTA beat in 8 of 12.
What analysts expect from ENTA
6 analysts cover Enanta Pharmaceuticals; their consensus rating is strong buy (4.83 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.83, 96.7% above the latest close of $11.10. Analysts expect earnings of −$2.29 per share for FY2026, +40.3% from a year earlier. For FY2027 the average estimate is −$2.37 per share on revenue of $63.7 million. Enanta Pharmaceuticals beat the EPS estimate in 8 of the last 12 quarters.
Related: ENTA income statement, ENTA key metrics, ENTA chart. See the ENTA stock overview for the latest quote and news.
ENTA forecast FAQ
What is Enanta Pharmaceuticals's price target?
The average analyst price target for Enanta Pharmaceuticals is $21.83, 96.7% above the latest close of $11.10.
Is Enanta Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering Enanta Pharmaceuticals, 5 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Enanta Pharmaceuticals's EPS forecast?
Analysts forecast −$2.29 per share for FY2026 (range −$2.49 to −$2.09); for FY2027 the estimate is −$2.37.
What is Enanta Pharmaceuticals's revenue forecast?
The average revenue estimate for FY2026 is $64.0 million, growth of −2.0%; for FY2027 it is $63.7 million.
When does Enanta Pharmaceuticals report earnings?
Enanta Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 16, 2026 after the market closes; the EPS estimate is $-0.82.
Does Enanta Pharmaceuticals usually beat earnings estimates?
Enanta Pharmaceuticals reported EPS at or above the analyst estimate in 8 of the last 12 quarters.